ES2627514T3 - Sistema de suministro de fármacos transdérmico y método de utilización del mismo - Google Patents
Sistema de suministro de fármacos transdérmico y método de utilización del mismo Download PDFInfo
- Publication number
- ES2627514T3 ES2627514T3 ES12802854.5T ES12802854T ES2627514T3 ES 2627514 T3 ES2627514 T3 ES 2627514T3 ES 12802854 T ES12802854 T ES 12802854T ES 2627514 T3 ES2627514 T3 ES 2627514T3
- Authority
- ES
- Spain
- Prior art keywords
- drug delivery
- pressure sensitive
- delivery system
- patch
- sensitive adhesive
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 238000013271 transdermal drug delivery Methods 0.000 title claims abstract description 55
- 238000000034 method Methods 0.000 title description 35
- 150000003431 steroids Chemical class 0.000 claims abstract description 75
- CBGUOGMQLZIXBE-XGQKBEPLSA-N clobetasol propionate Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CCl)(OC(=O)CC)[C@@]1(C)C[C@@H]2O CBGUOGMQLZIXBE-XGQKBEPLSA-N 0.000 claims abstract description 71
- 210000000744 eyelid Anatomy 0.000 claims abstract description 65
- 239000004820 Pressure-sensitive adhesive Substances 0.000 claims abstract description 60
- 229960004703 clobetasol propionate Drugs 0.000 claims abstract description 51
- 238000011282 treatment Methods 0.000 claims abstract description 34
- 239000010410 layer Substances 0.000 claims abstract description 26
- 229960003099 amcinonide Drugs 0.000 claims abstract description 24
- ILKJAFIWWBXGDU-MOGDOJJUSA-N amcinonide Chemical compound O([C@@]1([C@H](O2)C[C@@H]3[C@@]1(C[C@H](O)[C@]1(F)[C@@]4(C)C=CC(=O)C=C4CC[C@H]13)C)C(=O)COC(=O)C)C12CCCC1 ILKJAFIWWBXGDU-MOGDOJJUSA-N 0.000 claims abstract description 24
- 229960001102 betamethasone dipropionate Drugs 0.000 claims abstract description 16
- CIWBQSYVNNPZIQ-XYWKZLDCSA-N betamethasone dipropionate Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)COC(=O)CC)(OC(=O)CC)[C@@]1(C)C[C@@H]2O CIWBQSYVNNPZIQ-XYWKZLDCSA-N 0.000 claims abstract description 16
- DERCOWNWEPPIHD-UHFFFAOYSA-N [17-(2-chloroacetyl)-9-fluoro-11-hydroxy-10,13,16-trimethyl-3-oxo-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-17-yl] butanoate Chemical compound C1CC2=CC(=O)C=CC2(C)C2(F)C1C1CC(C)C(C(=O)CCl)(OC(=O)CCC)C1(C)CC2O DERCOWNWEPPIHD-UHFFFAOYSA-N 0.000 claims abstract description 13
- 208000029728 Eyelid disease Diseases 0.000 claims abstract description 10
- 201000010099 disease Diseases 0.000 claims description 20
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 20
- NIXOWILDQLNWCW-UHFFFAOYSA-N acrylic acid group Chemical group C(C=C)(=O)O NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 claims description 18
- 208000010217 blepharitis Diseases 0.000 claims description 18
- 229960001798 loteprednol Drugs 0.000 claims description 17
- 210000004175 meibomian gland Anatomy 0.000 claims description 12
- 230000004064 dysfunction Effects 0.000 claims description 11
- 229920001296 polysiloxane Polymers 0.000 claims description 9
- 229920001971 elastomer Polymers 0.000 claims description 7
- 239000005060 rubber Substances 0.000 claims description 7
- YPZVAYHNBBHPTO-MXRBDKCISA-N loteprednol Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)OCCl)[C@@H]4[C@@H]3CCC2=C1 YPZVAYHNBBHPTO-MXRBDKCISA-N 0.000 claims 1
- DMKSVUSAATWOCU-HROMYWEYSA-N loteprednol etabonate Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)OCCl)(OC(=O)OCC)[C@@]1(C)C[C@@H]2O DMKSVUSAATWOCU-HROMYWEYSA-N 0.000 abstract description 19
- 229960003744 loteprednol etabonate Drugs 0.000 abstract description 3
- 210000003491 skin Anatomy 0.000 description 42
- 239000002674 ointment Substances 0.000 description 35
- 238000000576 coating method Methods 0.000 description 25
- 206010030113 Oedema Diseases 0.000 description 23
- 239000004480 active ingredient Substances 0.000 description 23
- 239000011248 coating agent Substances 0.000 description 23
- 229960002842 clobetasol Drugs 0.000 description 21
- -1 heterocyclic spiro compound Chemical class 0.000 description 21
- 238000002360 preparation method Methods 0.000 description 20
- 239000000243 solution Substances 0.000 description 19
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 18
- 239000000853 adhesive Substances 0.000 description 18
- 230000001070 adhesive effect Effects 0.000 description 18
- 230000007794 irritation Effects 0.000 description 18
- 239000000203 mixture Substances 0.000 description 18
- 229920001525 carrageenan Polymers 0.000 description 15
- 239000000679 carrageenan Substances 0.000 description 15
- 229940113118 carrageenan Drugs 0.000 description 15
- 235000010418 carrageenan Nutrition 0.000 description 15
- 229940079593 drug Drugs 0.000 description 15
- 239000003814 drug Substances 0.000 description 15
- 229940068196 placebo Drugs 0.000 description 15
- 239000000902 placebo Substances 0.000 description 15
- UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 description 15
- 238000002347 injection Methods 0.000 description 14
- 239000007924 injection Substances 0.000 description 14
- 229960005205 prednisolone Drugs 0.000 description 13
- OIGNJSKKLXVSLS-VWUMJDOOSA-N prednisolone Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OIGNJSKKLXVSLS-VWUMJDOOSA-N 0.000 description 13
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 12
- 239000000463 material Substances 0.000 description 12
- 239000000126 substance Substances 0.000 description 12
- 206010015150 Erythema Diseases 0.000 description 11
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 11
- LRJOMUJRLNCICJ-JZYPGELDSA-N Prednisolone acetate Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)COC(=O)C)(O)[C@@]1(C)C[C@@H]2O LRJOMUJRLNCICJ-JZYPGELDSA-N 0.000 description 10
- 230000000694 effects Effects 0.000 description 10
- 239000000123 paper Substances 0.000 description 10
- 229960002800 prednisolone acetate Drugs 0.000 description 10
- 229920005989 resin Polymers 0.000 description 10
- 239000011347 resin Substances 0.000 description 10
- 229960002537 betamethasone Drugs 0.000 description 9
- UREBDLICKHMUKA-DVTGEIKXSA-N betamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-DVTGEIKXSA-N 0.000 description 9
- 230000037396 body weight Effects 0.000 description 9
- 231100000321 erythema Toxicity 0.000 description 9
- 239000007787 solid Substances 0.000 description 9
- 229960003957 dexamethasone Drugs 0.000 description 8
- 238000009472 formulation Methods 0.000 description 8
- 230000035515 penetration Effects 0.000 description 8
- 206010061218 Inflammation Diseases 0.000 description 7
- 241000700159 Rattus Species 0.000 description 7
- 125000000217 alkyl group Chemical group 0.000 description 7
- 230000004054 inflammatory process Effects 0.000 description 7
- 238000004898 kneading Methods 0.000 description 7
- 238000012360 testing method Methods 0.000 description 7
- 230000000699 topical effect Effects 0.000 description 7
- PIWKPBJCKXDKJR-UHFFFAOYSA-N Isoflurane Chemical compound FC(F)OC(Cl)C(F)(F)F PIWKPBJCKXDKJR-UHFFFAOYSA-N 0.000 description 6
- 241000283973 Oryctolagus cuniculus Species 0.000 description 6
- 230000015572 biosynthetic process Effects 0.000 description 6
- 229920001577 copolymer Polymers 0.000 description 6
- 239000010408 film Substances 0.000 description 6
- 239000012530 fluid Substances 0.000 description 6
- 230000004410 intraocular pressure Effects 0.000 description 6
- 229960002725 isoflurane Drugs 0.000 description 6
- 206010023332 keratitis Diseases 0.000 description 6
- 201000010666 keratoconjunctivitis Diseases 0.000 description 6
- 239000000178 monomer Substances 0.000 description 6
- VSKJLJHPAFKHBX-UHFFFAOYSA-N 2-methylbuta-1,3-diene;styrene Chemical compound CC(=C)C=C.C=CC1=CC=CC=C1.C=CC1=CC=CC=C1 VSKJLJHPAFKHBX-UHFFFAOYSA-N 0.000 description 5
- 206010010744 Conjunctivitis allergic Diseases 0.000 description 5
- 238000010521 absorption reaction Methods 0.000 description 5
- 208000002205 allergic conjunctivitis Diseases 0.000 description 5
- 208000024998 atopic conjunctivitis Diseases 0.000 description 5
- 230000002354 daily effect Effects 0.000 description 5
- 150000002148 esters Chemical class 0.000 description 5
- CYKDLUMZOVATFT-UHFFFAOYSA-N ethenyl acetate;prop-2-enoic acid Chemical compound OC(=O)C=C.CC(=O)OC=C CYKDLUMZOVATFT-UHFFFAOYSA-N 0.000 description 5
- 229940012356 eye drops Drugs 0.000 description 5
- 238000000338 in vitro Methods 0.000 description 5
- 208000015181 infectious disease Diseases 0.000 description 5
- 230000005764 inhibitory process Effects 0.000 description 5
- 230000007774 longterm Effects 0.000 description 5
- 238000002483 medication Methods 0.000 description 5
- 230000036556 skin irritation Effects 0.000 description 5
- NIXOWILDQLNWCW-UHFFFAOYSA-M Acrylate Chemical compound [O-]C(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-M 0.000 description 4
- 206010003694 Atrophy Diseases 0.000 description 4
- 241000894006 Bacteria Species 0.000 description 4
- 208000019300 CLIPPERS Diseases 0.000 description 4
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 4
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 4
- 206010015993 Eyelid oedema Diseases 0.000 description 4
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 4
- 206010020751 Hypersensitivity Diseases 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- 239000004743 Polypropylene Substances 0.000 description 4
- 206010040880 Skin irritation Diseases 0.000 description 4
- 206010069664 atopic keratoconjunctivitis Diseases 0.000 description 4
- 230000037444 atrophy Effects 0.000 description 4
- 208000021930 chronic lymphocytic inflammation with pontine perivascular enhancement responsive to steroids Diseases 0.000 description 4
- 210000000795 conjunctiva Anatomy 0.000 description 4
- 210000004087 cornea Anatomy 0.000 description 4
- 239000003431 cross linking reagent Substances 0.000 description 4
- 229960003657 dexamethasone acetate Drugs 0.000 description 4
- 238000012377 drug delivery Methods 0.000 description 4
- 238000001035 drying Methods 0.000 description 4
- 239000003889 eye drop Substances 0.000 description 4
- 239000000834 fixative Substances 0.000 description 4
- 239000003292 glue Substances 0.000 description 4
- 210000004209 hair Anatomy 0.000 description 4
- 239000004745 nonwoven fabric Substances 0.000 description 4
- 230000035699 permeability Effects 0.000 description 4
- 229920006267 polyester film Polymers 0.000 description 4
- 229920001155 polypropylene Polymers 0.000 description 4
- 229920000346 polystyrene-polyisoprene block-polystyrene Polymers 0.000 description 4
- 150000003839 salts Chemical class 0.000 description 4
- 231100000475 skin irritation Toxicity 0.000 description 4
- 239000004372 Polyvinyl alcohol Substances 0.000 description 3
- 208000003251 Pruritus Diseases 0.000 description 3
- 239000004902 Softening Agent Substances 0.000 description 3
- 239000013543 active substance Substances 0.000 description 3
- 239000012790 adhesive layer Substances 0.000 description 3
- 208000026935 allergic disease Diseases 0.000 description 3
- 230000000172 allergic effect Effects 0.000 description 3
- 230000007815 allergy Effects 0.000 description 3
- 208000010668 atopic eczema Diseases 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 239000002131 composite material Substances 0.000 description 3
- 230000003247 decreasing effect Effects 0.000 description 3
- 239000006196 drop Substances 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 208000030533 eye disease Diseases 0.000 description 3
- 239000004744 fabric Substances 0.000 description 3
- 230000003779 hair growth Effects 0.000 description 3
- 239000012943 hotmelt Substances 0.000 description 3
- 230000007803 itching Effects 0.000 description 3
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
- 229920001225 polyester resin Polymers 0.000 description 3
- 239000004645 polyester resin Substances 0.000 description 3
- 229920000139 polyethylene terephthalate Polymers 0.000 description 3
- 239000005020 polyethylene terephthalate Substances 0.000 description 3
- 229920002451 polyvinyl alcohol Polymers 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- 231100000161 signs of toxicity Toxicity 0.000 description 3
- 231100000245 skin permeability Toxicity 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 238000011200 topical administration Methods 0.000 description 3
- 230000002110 toxicologic effect Effects 0.000 description 3
- 231100000027 toxicology Toxicity 0.000 description 3
- 229920001567 vinyl ester resin Polymers 0.000 description 3
- RSWGJHLUYNHPMX-UHFFFAOYSA-N Abietic-Saeure Natural products C12CCC(C(C)C)=CC2=CCC2C1(C)CCCC2(C)C(O)=O RSWGJHLUYNHPMX-UHFFFAOYSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 208000002177 Cataract Diseases 0.000 description 2
- 206010010741 Conjunctivitis Diseases 0.000 description 2
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 2
- 208000001840 Dandruff Diseases 0.000 description 2
- 208000010412 Glaucoma Diseases 0.000 description 2
- XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 239000004698 Polyethylene Substances 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- 229920002367 Polyisobutene Polymers 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 2
- ZTHYODDOHIVTJV-UHFFFAOYSA-N Propyl gallate Chemical compound CCCOC(=O)C1=CC(O)=C(O)C(O)=C1 ZTHYODDOHIVTJV-UHFFFAOYSA-N 0.000 description 2
- 241000700157 Rattus norvegicus Species 0.000 description 2
- 229920000297 Rayon Polymers 0.000 description 2
- KHPCPRHQVVSZAH-HUOMCSJISA-N Rosin Natural products O(C/C=C/c1ccccc1)[C@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 KHPCPRHQVVSZAH-HUOMCSJISA-N 0.000 description 2
- 206010040914 Skin reaction Diseases 0.000 description 2
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 description 2
- 239000002250 absorbent Substances 0.000 description 2
- 230000002745 absorbent Effects 0.000 description 2
- 239000013566 allergen Substances 0.000 description 2
- 230000003110 anti-inflammatory effect Effects 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 230000003078 antioxidant effect Effects 0.000 description 2
- 230000003115 biocidal effect Effects 0.000 description 2
- 238000003490 calendering Methods 0.000 description 2
- 125000004432 carbon atom Chemical group C* 0.000 description 2
- 229910002092 carbon dioxide Inorganic materials 0.000 description 2
- 239000001569 carbon dioxide Substances 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 239000003246 corticosteroid Substances 0.000 description 2
- 239000006185 dispersion Substances 0.000 description 2
- 231100000673 dose–response relationship Toxicity 0.000 description 2
- 229960003449 epinastine Drugs 0.000 description 2
- WHWZLSFABNNENI-UHFFFAOYSA-N epinastine Chemical compound C1C2=CC=CC=C2C2CN=C(N)N2C2=CC=CC=C21 WHWZLSFABNNENI-UHFFFAOYSA-N 0.000 description 2
- 230000003203 everyday effect Effects 0.000 description 2
- 239000003885 eye ointment Substances 0.000 description 2
- 210000000720 eyelash Anatomy 0.000 description 2
- 239000000945 filler Substances 0.000 description 2
- 239000003862 glucocorticoid Substances 0.000 description 2
- 230000035876 healing Effects 0.000 description 2
- 229960001340 histamine Drugs 0.000 description 2
- 238000010030 laminating Methods 0.000 description 2
- 230000003902 lesion Effects 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 229960004114 olopatadine Drugs 0.000 description 2
- JBIMVDZLSHOPLA-LSCVHKIXSA-N olopatadine Chemical compound C1OC2=CC=C(CC(O)=O)C=C2C(=C/CCN(C)C)\C2=CC=CC=C21 JBIMVDZLSHOPLA-LSCVHKIXSA-N 0.000 description 2
- 229940069265 ophthalmic ointment Drugs 0.000 description 2
- 239000003960 organic solvent Substances 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 239000002504 physiological saline solution Substances 0.000 description 2
- 229920003207 poly(ethylene-2,6-naphthalate) Polymers 0.000 description 2
- 229920001707 polybutylene terephthalate Polymers 0.000 description 2
- 229920000573 polyethylene Polymers 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 239000011112 polyethylene naphthalate Substances 0.000 description 2
- 229920005672 polyolefin resin Polymers 0.000 description 2
- 229920002635 polyurethane Polymers 0.000 description 2
- 239000004814 polyurethane Substances 0.000 description 2
- 239000002964 rayon Substances 0.000 description 2
- 239000000018 receptor agonist Substances 0.000 description 2
- 229940044601 receptor agonist Drugs 0.000 description 2
- 230000035483 skin reaction Effects 0.000 description 2
- 231100000430 skin reaction Toxicity 0.000 description 2
- KHPCPRHQVVSZAH-UHFFFAOYSA-N trans-cinnamyl beta-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OCC=CC1=CC=CC=C1 KHPCPRHQVVSZAH-UHFFFAOYSA-N 0.000 description 2
- 238000004704 ultra performance liquid chromatography Methods 0.000 description 2
- 239000005526 vasoconstrictor agent Substances 0.000 description 2
- SGKRLCUYIXIAHR-AKNGSSGZSA-N (4s,4ar,5s,5ar,6r,12ar)-4-(dimethylamino)-1,5,10,11,12a-pentahydroxy-6-methyl-3,12-dioxo-4a,5,5a,6-tetrahydro-4h-tetracene-2-carboxamide Chemical compound C1=CC=C2[C@H](C)[C@@H]([C@H](O)[C@@H]3[C@](C(O)=C(C(N)=O)C(=O)[C@H]3N(C)C)(O)C3=O)C3=C(O)C2=C1O SGKRLCUYIXIAHR-AKNGSSGZSA-N 0.000 description 1
- FFTVPQUHLQBXQZ-KVUCHLLUSA-N (4s,4as,5ar,12ar)-4,7-bis(dimethylamino)-1,10,11,12a-tetrahydroxy-3,12-dioxo-4a,5,5a,6-tetrahydro-4h-tetracene-2-carboxamide Chemical compound C1C2=C(N(C)C)C=CC(O)=C2C(O)=C2[C@@H]1C[C@H]1[C@H](N(C)C)C(=O)C(C(N)=O)=C(O)[C@@]1(O)C2=O FFTVPQUHLQBXQZ-KVUCHLLUSA-N 0.000 description 1
- SMZOUWXMTYCWNB-UHFFFAOYSA-N 2-(2-methoxy-5-methylphenyl)ethanamine Chemical compound COC1=CC=C(C)C=C1CCN SMZOUWXMTYCWNB-UHFFFAOYSA-N 0.000 description 1
- GOXQRTZXKQZDDN-UHFFFAOYSA-N 2-Ethylhexyl acrylate Chemical compound CCCCC(CC)COC(=O)C=C GOXQRTZXKQZDDN-UHFFFAOYSA-N 0.000 description 1
- NJMYQRVWBCSLEU-UHFFFAOYSA-N 4-hydroxy-2-methylidenebutanoic acid Chemical compound OCCC(=C)C(O)=O NJMYQRVWBCSLEU-UHFFFAOYSA-N 0.000 description 1
- CUXGDKOCSSIRKK-UHFFFAOYSA-N 7-methyloctyl prop-2-enoate Chemical compound CC(C)CCCCCCOC(=O)C=C CUXGDKOCSSIRKK-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 206010003645 Atopy Diseases 0.000 description 1
- 201000004569 Blindness Diseases 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- NLZUEZXRPGMBCV-UHFFFAOYSA-N Butylhydroxytoluene Chemical compound CC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 NLZUEZXRPGMBCV-UHFFFAOYSA-N 0.000 description 1
- FERIUCNNQQJTOY-UHFFFAOYSA-M Butyrate Chemical compound CCCC([O-])=O FERIUCNNQQJTOY-UHFFFAOYSA-M 0.000 description 1
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Natural products CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 1
- 208000004434 Calcinosis Diseases 0.000 description 1
- 229920004939 Cariflex™ Polymers 0.000 description 1
- 206010007764 Cataract subcapsular Diseases 0.000 description 1
- 229920000298 Cellophane Polymers 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 208000003322 Coinfection Diseases 0.000 description 1
- 229920000742 Cotton Polymers 0.000 description 1
- 108010036949 Cyclosporine Proteins 0.000 description 1
- 208000003556 Dry Eye Syndromes Diseases 0.000 description 1
- 206010013774 Dry eye Diseases 0.000 description 1
- 229920000219 Ethylene vinyl alcohol Polymers 0.000 description 1
- 208000001860 Eye Infections Diseases 0.000 description 1
- 206010015995 Eyelid ptosis Diseases 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 244000043261 Hevea brasiliensis Species 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- 206010065062 Meibomian gland dysfunction Diseases 0.000 description 1
- CERQOIWHTDAKMF-UHFFFAOYSA-N Methacrylic acid Chemical compound CC(=C)C(O)=O CERQOIWHTDAKMF-UHFFFAOYSA-N 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 208000006550 Mydriasis Diseases 0.000 description 1
- 206010030043 Ocular hypertension Diseases 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 206010033546 Pallor Diseases 0.000 description 1
- 239000004952 Polyamide Substances 0.000 description 1
- 239000005062 Polybutadiene Substances 0.000 description 1
- 239000004793 Polystyrene Substances 0.000 description 1
- 206010039509 Scab Diseases 0.000 description 1
- 206010039792 Seborrhoea Diseases 0.000 description 1
- 239000004098 Tetracycline Substances 0.000 description 1
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 1
- 206010046851 Uveitis Diseases 0.000 description 1
- 206010053648 Vascular occlusion Diseases 0.000 description 1
- XTXRWKRVRITETP-UHFFFAOYSA-N Vinyl acetate Chemical compound CC(=O)OC=C XTXRWKRVRITETP-UHFFFAOYSA-N 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- FPVRUILUEYSIMD-RPRRAYFGSA-N [(8s,9r,10s,11s,13s,14s,16r,17r)-9-fluoro-11-hydroxy-17-(2-hydroxyacetyl)-10,13,16-trimethyl-3-oxo-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-17-yl] acetate Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(OC(C)=O)[C@@]1(C)C[C@@H]2O FPVRUILUEYSIMD-RPRRAYFGSA-N 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 238000005299 abrasion Methods 0.000 description 1
- YBCVMFKXIKNREZ-UHFFFAOYSA-N acoh acetic acid Chemical compound CC(O)=O.CC(O)=O YBCVMFKXIKNREZ-UHFFFAOYSA-N 0.000 description 1
- 150000001252 acrylic acid derivatives Chemical class 0.000 description 1
- 150000001253 acrylic acids Chemical class 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 238000011374 additional therapy Methods 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 229940124599 anti-inflammatory drug Drugs 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000001588 bifunctional effect Effects 0.000 description 1
- 229920001400 block copolymer Polymers 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- CQEYYJKEWSMYFG-UHFFFAOYSA-N butyl acrylate Chemical compound CCCCOC(=O)C=C CQEYYJKEWSMYFG-UHFFFAOYSA-N 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 229960001265 ciclosporin Drugs 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 229960001334 corticosteroids Drugs 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 230000001186 cumulative effect Effects 0.000 description 1
- 229930182912 cyclosporin Natural products 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 230000035614 depigmentation Effects 0.000 description 1
- 210000004207 dermis Anatomy 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 229960003722 doxycycline Drugs 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 230000002500 effect on skin Effects 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 238000007720 emulsion polymerization reaction Methods 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 210000002615 epidermis Anatomy 0.000 description 1
- 229950009769 etabonate Drugs 0.000 description 1
- GLVVKKSPKXTQRB-UHFFFAOYSA-N ethenyl dodecanoate Chemical compound CCCCCCCCCCCC(=O)OC=C GLVVKKSPKXTQRB-UHFFFAOYSA-N 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 208000011323 eye infectious disease Diseases 0.000 description 1
- 230000004438 eyesight Effects 0.000 description 1
- 238000009093 first-line therapy Methods 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 238000010528 free radical solution polymerization reaction Methods 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 230000002650 habitual effect Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 210000003630 histaminocyte Anatomy 0.000 description 1
- 210000002287 horizontal cell Anatomy 0.000 description 1
- 208000013403 hyperactivity Diseases 0.000 description 1
- 229960004716 idoxuridine Drugs 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- KQNPFQTWMSNSAP-UHFFFAOYSA-N isobutyric acid Chemical compound CC(C)C(O)=O KQNPFQTWMSNSAP-UHFFFAOYSA-N 0.000 description 1
- 239000002655 kraft paper Substances 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 229960004023 minocycline Drugs 0.000 description 1
- 239000012046 mixed solvent Substances 0.000 description 1
- 229920003052 natural elastomer Polymers 0.000 description 1
- 229920001194 natural rubber Polymers 0.000 description 1
- 238000011587 new zealand white rabbit Methods 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- MDYPDLBFDATSCF-UHFFFAOYSA-N nonyl prop-2-enoate Chemical compound CCCCCCCCCOC(=O)C=C MDYPDLBFDATSCF-UHFFFAOYSA-N 0.000 description 1
- 229940065472 octyl acrylate Drugs 0.000 description 1
- ANISOHQJBAQUQP-UHFFFAOYSA-N octyl prop-2-enoate Chemical compound CCCCCCCCOC(=O)C=C ANISOHQJBAQUQP-UHFFFAOYSA-N 0.000 description 1
- 201000005111 ocular hyperemia Diseases 0.000 description 1
- 230000037312 oily skin Effects 0.000 description 1
- 239000011088 parchment paper Substances 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 239000003208 petroleum Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000004014 plasticizer Substances 0.000 description 1
- 229920001483 poly(ethyl methacrylate) polymer Polymers 0.000 description 1
- 229920001200 poly(ethylene-vinyl acetate) Polymers 0.000 description 1
- 229920003229 poly(methyl methacrylate) Polymers 0.000 description 1
- 229920002492 poly(sulfone) Polymers 0.000 description 1
- 229920002239 polyacrylonitrile Polymers 0.000 description 1
- 229920002647 polyamide Polymers 0.000 description 1
- 229920000768 polyamine Polymers 0.000 description 1
- 229920002857 polybutadiene Polymers 0.000 description 1
- 229920001083 polybutene Polymers 0.000 description 1
- 229920001748 polybutylene Polymers 0.000 description 1
- 229920001195 polyisoprene Polymers 0.000 description 1
- 239000004926 polymethyl methacrylate Substances 0.000 description 1
- 229920002223 polystyrene Polymers 0.000 description 1
- 239000004800 polyvinyl chloride Substances 0.000 description 1
- 229920000915 polyvinyl chloride Polymers 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 230000002980 postoperative effect Effects 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 239000000473 propyl gallate Substances 0.000 description 1
- 229940075579 propyl gallate Drugs 0.000 description 1
- 235000010388 propyl gallate Nutrition 0.000 description 1
- 201000003004 ptosis Diseases 0.000 description 1
- 238000002271 resection Methods 0.000 description 1
- 229940053174 restasis Drugs 0.000 description 1
- 230000002207 retinal effect Effects 0.000 description 1
- 230000018040 scab formation Effects 0.000 description 1
- 238000007790 scraping Methods 0.000 description 1
- 210000001732 sebaceous gland Anatomy 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000003892 spreading Methods 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 229920003048 styrene butadiene rubber Polymers 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 238000010557 suspension polymerization reaction Methods 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 230000004489 tear production Effects 0.000 description 1
- 229960002180 tetracycline Drugs 0.000 description 1
- 229930101283 tetracycline Natural products 0.000 description 1
- 235000019364 tetracycline Nutrition 0.000 description 1
- 150000003522 tetracyclines Chemical class 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- OGIDPMRJRNCKJF-UHFFFAOYSA-N titanium oxide Inorganic materials [Ti]=O OGIDPMRJRNCKJF-UHFFFAOYSA-N 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 229960002117 triamcinolone acetonide Drugs 0.000 description 1
- YNDXUCZADRHECN-JNQJZLCISA-N triamcinolone acetonide Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@@H]2O YNDXUCZADRHECN-JNQJZLCISA-N 0.000 description 1
- 239000006097 ultraviolet radiation absorber Substances 0.000 description 1
- 229940070710 valerate Drugs 0.000 description 1
- NQPDZGIKBAWPEJ-UHFFFAOYSA-N valeric acid Chemical compound CCCCC(O)=O NQPDZGIKBAWPEJ-UHFFFAOYSA-N 0.000 description 1
- 239000006200 vaporizer Substances 0.000 description 1
- 208000021331 vascular occlusion disease Diseases 0.000 description 1
- 230000024883 vasodilation Effects 0.000 description 1
- 230000004304 visual acuity Effects 0.000 description 1
- 230000004393 visual impairment Effects 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 239000002759 woven fabric Substances 0.000 description 1
- 239000011787 zinc oxide Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
- A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
- A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
- A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
- A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
- A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
- A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
- A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
- A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
- A61K9/7061—Polyacrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Dermatology (AREA)
- Ophthalmology & Optometry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201113164037 | 2011-06-20 | ||
| US13/164,037 US8900626B2 (en) | 2011-06-20 | 2011-06-20 | Transdermal drug delivery system and method of using the same |
| PCT/US2012/043126 WO2012177626A1 (en) | 2011-06-20 | 2012-06-19 | Transdermal drug delivery system and method of using the same |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2627514T3 true ES2627514T3 (es) | 2017-07-28 |
Family
ID=47353860
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES12802854.5T Active ES2627514T3 (es) | 2011-06-20 | 2012-06-19 | Sistema de suministro de fármacos transdérmico y método de utilización del mismo |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US8900626B2 (https=) |
| EP (1) | EP2720748B1 (https=) |
| JP (2) | JP6296977B2 (https=) |
| KR (2) | KR20190026963A (https=) |
| CN (1) | CN103429295B (https=) |
| CA (1) | CA2831095C (https=) |
| ES (1) | ES2627514T3 (https=) |
| MX (1) | MX347195B (https=) |
| WO (1) | WO2012177626A1 (https=) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20060036220A1 (en) * | 2003-01-22 | 2006-02-16 | Kohji Kawahara | Percutaneous absorption preparation for treating ophthalmic disease, use thereof and method for migration of ophthalmic remedy into topical tissue in eye |
| US8950405B2 (en) * | 2006-05-15 | 2015-02-10 | Tearscience, Inc. | Treatment of obstructive disorders of the eye or eyelid |
| US20090043365A1 (en) | 2005-07-18 | 2009-02-12 | Kolis Scientific, Inc. | Methods, apparatuses, and systems for reducing intraocular pressure as a means of preventing or treating open-angle glaucoma |
| US7981145B2 (en) | 2005-07-18 | 2011-07-19 | Tearscience Inc. | Treatment of meibomian glands |
| WO2013003594A2 (en) | 2011-06-28 | 2013-01-03 | Tearscience, Inc. | Methods and systems for treating meibomian gland dysfunction using radio-frequency energy |
| US8083787B2 (en) | 2005-07-18 | 2011-12-27 | Tearscience, Inc. | Method and apparatus for treating meibomian gland dysfunction |
| US20080114423A1 (en) | 2006-05-15 | 2008-05-15 | Grenon Stephen M | Apparatus for inner eyelid treatment of meibomian gland dysfunction |
| US20070060988A1 (en) | 2005-07-18 | 2007-03-15 | Grenon Stephen M | Melting meibomian gland obstructions |
| US9314369B2 (en) | 2006-05-15 | 2016-04-19 | Tearscience, Inc. | System for inner eyelid treatment of meibomian gland dysfunction |
| US10842670B2 (en) | 2012-08-22 | 2020-11-24 | Johnson & Johnson Vision Care, Inc. | Apparatuses and methods for diagnosing and/or treating lipid transport deficiency in ocular tear films, and related components and devices |
| US9211397B2 (en) * | 2012-12-19 | 2015-12-15 | Senju Usa, Inc. | Patch for treatment of eyelid disease containing clobetasol |
| US9820954B2 (en) | 2015-08-19 | 2017-11-21 | Jenivision Inc. | Quantitative peri-orbital application of ophthalmology drugs |
| US12011388B2 (en) | 2016-03-01 | 2024-06-18 | The Hilsinger Company Parent, Llc | Therapeutic thermal compress with phase-change material |
| US12156831B2 (en) | 2016-03-01 | 2024-12-03 | The Hilsinger Company Parent, Llc | Therapeutic eye compress system |
| US12029681B2 (en) | 2016-03-01 | 2024-07-09 | The Hilsinger Company Parent, Llc | Therapeutic eye mask system |
| WO2018003952A1 (ja) * | 2016-06-29 | 2018-01-04 | センジュ ユーエスエー、インコーポレイテッド | 経皮薬物送達システムおよびその使用方法 |
| USD871598S1 (en) | 2016-11-30 | 2019-12-31 | Bruder Healthcare Company, Llc | Therapeutic eye mask |
| USD844795S1 (en) | 2016-11-30 | 2019-04-02 | Bruder Healthcare Company, Llc | Therapeutic eye mask |
| IL274810B2 (en) * | 2017-11-21 | 2025-12-01 | Axerovision Inc | Compositions and methods of use for treating aberrant inflammation in peri-ocular secretory glands or at the ocular surface |
| US11759472B2 (en) | 2017-11-21 | 2023-09-19 | Cs Pharmaceuticals Limited | Compositions and methods of use for treating aberrant inflammation in peri-ocular secretory glands or at the ocular surface |
| WO2019133690A1 (en) * | 2017-12-28 | 2019-07-04 | Nichiban Co., Ltd. | Transdermal drug delivery system and method for using same |
| US11554048B2 (en) | 2018-03-02 | 2023-01-17 | The Schepens Eye Research Institute, Inc. | System and method for treating meibomian gland dysfunction |
| WO2022010864A1 (en) * | 2020-07-06 | 2022-01-13 | Kindeva Drug Delivery L.P. | Drug delivery device for delivery of clobetasol propionate |
| WO2022109497A1 (en) | 2020-11-23 | 2022-05-27 | Sight Sciences, Inc. | Formulations and methods for treating conditions of the eye |
Family Cites Families (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1047519A (en) | 1963-06-11 | 1966-11-02 | Glaxo Lab Ltd | 17ª‡,21-diesters of 11,17,21-trihydroxy steroid compounds |
| GB1253831A (en) | 1968-01-19 | 1971-11-17 | Glaxo Lab Ltd | 9alpha,21-DIHALOPREGNANE COMPOUNDS |
| ZA744259B (en) | 1973-08-17 | 1975-06-25 | American Cyanamid Co | Topical steroid |
| US4666441A (en) | 1985-12-17 | 1987-05-19 | Ciba-Geigy Corporation | Multicompartmentalized transdermal patches |
| US4954343A (en) * | 1986-03-29 | 1990-09-04 | Nitto Electric Industrial Co., Ltd. | Dermal pharmaceutical preparations |
| ATE90355T1 (de) | 1987-10-13 | 1993-06-15 | Nicholas S Bodor | Weiche steroide mit anti-entzuendungswirkung. |
| ZA966579B (en) * | 1995-08-04 | 1998-02-02 | Wakamoto Pharma Co Ltd | O/W emulsion composition for eye drops. |
| JP2001009985A (ja) * | 1999-07-02 | 2001-01-16 | Hisamitsu Pharmaceut Co Inc | 貼付剤用包装袋及び包装貼付剤 |
| WO2001026648A1 (en) | 1999-10-13 | 2001-04-19 | Senju Pharmaceutical Co., Ltd. | Ophthalmic adhesive preparations for percutaneous absorption |
| US20050058695A1 (en) * | 2002-05-30 | 2005-03-17 | Watson Pharmaccuticals, Inc. | Norethindrone sustained release formulations and methods associated therewith |
| US20060036220A1 (en) | 2003-01-22 | 2006-02-16 | Kohji Kawahara | Percutaneous absorption preparation for treating ophthalmic disease, use thereof and method for migration of ophthalmic remedy into topical tissue in eye |
| SI1755616T1 (sl) * | 2004-04-08 | 2014-04-30 | Eye Co Pty Ltd. | Zdravljenje eksudativne retinopatije z mineralkortikoidi |
| US7754230B2 (en) * | 2004-05-19 | 2010-07-13 | The Regents Of The University Of California | Methods and related compositions for reduction of fat |
| PL1754491T3 (pl) | 2004-05-21 | 2010-08-31 | Senju Pharma Co | Preparat do oczu do wchłaniania przezskórnego zawierający agonistę receptora muskarynowego |
| EP1852106A4 (en) | 2005-02-17 | 2009-08-26 | Senju Pharma Co | SOLID OPHTHALMIC MEDICINE FOR EXTERNAL USE |
| EP1872390A2 (en) * | 2005-04-11 | 2008-01-02 | The Board of Trustees of the Leland Stanford Junior University | Multi-layer structure having a predetermined layer pattern including an agent |
| JP5315051B2 (ja) | 2005-07-08 | 2013-10-16 | 千寿製薬株式会社 | オロパタジンを含む眼科用経皮吸収型製剤 |
| JP2009500397A (ja) | 2005-07-08 | 2009-01-08 | 千寿製薬株式会社 | エピナスチンを含む眼科用経皮吸収型製剤 |
| WO2007013661A1 (ja) | 2005-07-26 | 2007-02-01 | Senju Pharmaceutical Co., Ltd. | 眼科用経皮吸収型製剤 |
| US20090318422A1 (en) | 2006-08-28 | 2009-12-24 | Akiharu Isowaki | Ophthalmic percutaneous absorption type preparation |
| EP2258369B1 (en) | 2008-02-27 | 2015-04-08 | Hisamitsu Pharmaceutical Co., Inc. | Medicated patch |
| US20090297590A1 (en) | 2008-05-30 | 2009-12-03 | Masahiro Yamaji | Ketotifen transdermal drug delivery systems and methods for treating ophthalmic disease |
| JP5421910B2 (ja) * | 2008-06-19 | 2014-02-19 | 学校法人近畿大学 | ペプチド誘導体およびそれを含む涙液分泌促進組成物 |
| US10201548B2 (en) | 2009-03-06 | 2019-02-12 | Sun Pharma Global Fze | Methods for treating ocular inflammatory diseases |
| TW201039815A (en) * | 2009-04-13 | 2010-11-16 | Resolvyx Pharmaceuticals Inc | Compositions and methods for the treatment of inflammation |
| JO3257B1 (ar) * | 2009-09-02 | 2018-09-16 | Novartis Ag | مركبات وتركيبات كمعدلات لفاعلية tlr |
| LT2493474T (lt) | 2009-10-30 | 2019-10-10 | Intratus, Inc. | Būdai ir kompozicijos prolonguotam vaistų įvedimui |
| US9944172B2 (en) * | 2010-03-31 | 2018-04-17 | Kiekert Ag | Actuator for a motor vehicle and locking device and method |
| EP2505618A1 (en) * | 2011-04-01 | 2012-10-03 | Fábrica Nacional De Moneda Y Timbre | Use of electromagnetic wave absorbing markers for the aunthentication of security documents |
-
2011
- 2011-06-20 US US13/164,037 patent/US8900626B2/en not_active Expired - Fee Related
-
2012
- 2012-06-19 CN CN201280006627.7A patent/CN103429295B/zh not_active Expired - Fee Related
- 2012-06-19 WO PCT/US2012/043126 patent/WO2012177626A1/en not_active Ceased
- 2012-06-19 ES ES12802854.5T patent/ES2627514T3/es active Active
- 2012-06-19 MX MX2013008543A patent/MX347195B/es active IP Right Grant
- 2012-06-19 KR KR1020197006444A patent/KR20190026963A/ko not_active Ceased
- 2012-06-19 EP EP12802854.5A patent/EP2720748B1/en not_active Not-in-force
- 2012-06-19 KR KR1020137025876A patent/KR102107977B1/ko not_active Expired - Fee Related
- 2012-06-19 CA CA2831095A patent/CA2831095C/en not_active Expired - Fee Related
- 2012-06-19 JP JP2014517085A patent/JP6296977B2/ja not_active Expired - Fee Related
-
2016
- 2016-10-14 JP JP2016202990A patent/JP2017048201A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US8900626B2 (en) | 2014-12-02 |
| CN103429295A (zh) | 2013-12-04 |
| KR102107977B1 (ko) | 2020-05-07 |
| JP2014519955A (ja) | 2014-08-21 |
| EP2720748B1 (en) | 2017-05-17 |
| EP2720748A4 (en) | 2014-11-26 |
| US20120321673A1 (en) | 2012-12-20 |
| CN103429295B (zh) | 2017-03-29 |
| CA2831095A1 (en) | 2012-12-27 |
| MX347195B (es) | 2017-04-19 |
| MX2013008543A (es) | 2013-08-12 |
| EP2720748A1 (en) | 2014-04-23 |
| WO2012177626A1 (en) | 2012-12-27 |
| CA2831095C (en) | 2015-12-01 |
| JP2017048201A (ja) | 2017-03-09 |
| KR20140019790A (ko) | 2014-02-17 |
| JP6296977B2 (ja) | 2018-03-20 |
| KR20190026963A (ko) | 2019-03-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2627514T3 (es) | Sistema de suministro de fármacos transdérmico y método de utilización del mismo | |
| ES2534904T3 (es) | Preparación de absorción percutánea para el tratamiento de enfermedad oftálmica, uso del mismo y método para la migración del remedio oftálmico en el tejido tópico en los ojos | |
| JP5020061B2 (ja) | 経皮吸収型製剤 | |
| US6239177B1 (en) | Tranilast-containing preparation for external application and method of producing the same | |
| KR100209469B1 (ko) | N-치환-o-톨루이딘유도체로 이루어진 약용배합제 및 경피흡수형 제제 | |
| ES2666143T3 (es) | Parche para el tratamiento de enfermedades de los párpados que contiene clobetasol | |
| JP7183041B2 (ja) | 経皮薬物送達システムおよびその使用方法 | |
| JP4308255B2 (ja) | ムスカリン受容体作動薬を含有する眼科用経皮吸収型製剤 | |
| KR20020012549A (ko) | 옥시부티닌 함유 경피흡수 제제 | |
| WO2015129527A1 (ja) | プラミペキソールを含有する神経変性疾患の治療用貼付剤 | |
| ES2304989T3 (es) | Agente antiprurigonoso para uso externo. | |
| ES2623533T3 (es) | Parche adhesivo de baja irritación | |
| JP2001058961A (ja) | 経皮吸収促進剤及び経皮吸収型製剤 | |
| JPH01297069A (ja) | 粘着剤組成物 | |
| JP2001233764A (ja) | Ｎ−置換−ｏ−トルイジン誘導体からなる鎮痒剤 | |
| CA2244679C (en) | Tranilast-containing preparation for external application and method of producing the same | |
| JP2002097134A (ja) | オキセサゼインを有効成分とする皮膚外用剤 | |
| JP2004292341A (ja) | ケロイド等の形成抑制外用剤 | |
| JPWO2001026648A1 (ja) | 眼科用経皮吸収貼付剤 | |
| ZA200606351B (en) | Remedy for external use for skin and mucosal injuries caused by viral infection |